Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFA calcium absorption PoC after Roux-en-Y gastric bypass
2024-511124-14-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- May 2024
- Modality
- Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bafilomycin A1, glycocholate and sodium butyrate in obesity, hypocalcemia, secondary hyperparathyroidism (SHPT) and 1 more, sponsored by Region Västra Götaland. Primary endpoint: Safety and tolerability of BAFA. Planned start May 2024; status: authorised.
02
Drugs
bafilomycin A1glycocholatesodium butyrate
03
Conditions
obesityhypocalcemiasecondary hyperparathyroidism (SHPT)Metabolic osteopathies
Beyond the preview
Go deeper on 2024-511124-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511124-14-00.